Clinical Trials on PIK3CA Mutation in South Africa

Total 78 results

Faeth Therapeutics

Active, not recruiting

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Advanced Solid Tumor | PIK3CA Mutation | PTEN Loss of Function Mutation

United States
AstraZeneca

Completed

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

Advanced Solid Malignancies | Breast Cancer - ER+, HER2 - | Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation

United States, United Kingdom
University of Stellenbosch

Completed

Penile Transplant Study

Penile Amputation

South Africa
Prisma Health-Upstate
Ipsen

Recruiting

Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Solid Tumor | ARID1A Gene Mutation

United States
Nested Therapeutics, Inc

Recruiting

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NST-628)

Glioma | Melanoma | NSCLC | Oncology | Solid Tumor, Adult | MEK Mutation | RAF Gene Mutation | Ras (KRAS or NRAS) Gene Mutation | MAPK Pathway Gene Mutation

United States, Australia
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | ATR Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CHEK1 Gene Mutation | FANCA Gene... and other conditions

United States, Canada
BioMed Valley Discoveries, Inc

Terminated

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Advanced Solid Tumor | MAP2K1 Gene Mutation | BRAF Gene Mutation | MEK Mutation | BRAF Gene Alteration | MEK Alteration | MAP2K1 Gene Alteration | MAP2K2 Gene Mutation | MAP2K2 Gene Alteration

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...
Worldwide Clinical Trials

Terminated

Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002) (MOSAIC)

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome

United States, Australia, Italy, Spain
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)

United States, Australia, Brazil, Italy, United Kingdom
D3 Bio (Wuxi) Co., Ltd

Recruiting

Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

Advanced Solid Tumors With MAPK Pathway Mutations

Australia, China, United States
MapKure, LLC

Recruiting

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Solid Tumor | B-Raf Mutation-Related Tumors

United States, Australia
Pfizer

Completed

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Solid Tumors Harboring a BRAF V600 Mutation

United States, France, Italy, Singapore, Australia, Spain, Switzerland, Canada, Belgium
Universidad de Costa Rica

Unknown

Genetic Markers of Circulating Tumor DNA for Monitoring Breast Cancer Patients in Costa Rica

Metastatic Breast Cancer | Mutation, Point

Costa Rica
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

Breast Cancer | brca1 Mutation Carrier | brca2 Mutation Carrier

United States
AstraZeneca

Completed

Asia Pacific and Russia Diagnostic Study for EGFR Testing (IGNITE)

EGFR Mutation Status in aNSCLC Patients

Korea, Republic of, Russian Federation, Malaysia, China, Australia, Taiwan, Thailand, Indonesia, Singapore
Incyte Corporation

Terminated

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

Advanced or Metastatic Solid Tumors | FGFR Mutations | FGFR Translocations

United States
Pfizer
Medivation, Inc.

Completed

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Korea, Republic of, United States, Australia, Spain, Belgium, France, Ireland, Taiwan, Poland, Germany, Israel, Brazil, United Kingdom, Italy, Russian Federation, Ukraine
AstraZeneca

No longer available

AZD9291 US Expanded Access Program

EGFR T790M Mutation Positive NSCLC

United States
Amgen

Recruiting

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Advanced Solid Tumors | Kirsten Rat Sarcoma (KRAS) pG12C Mutation

United States, Italy, Taiwan, Spain, United Kingdom, Australia, Austria, Germany, Belgium, Japan, Netherlands, Korea, Republic of, Canada
Otto Bock Healthcare Products GmbH
Hanger Clinic: Prosthetics & Orthotics

Active, not recruiting

Assessing Outcomes With Microprocessor Knee Utilization in a K2 Population (ASCENT K2)

Lower Limb Amputation Above Knee (Injury) | Lower Limb Amputation Knee | Congenital Amputation of Lower Limb

United States
Universidad de Costa Rica
Universitat Autonoma de Barcelona

Unknown

C677T and A1298C MTHFR Polymorphisms and Fluoropyrimidine Effectiveness in Metastatic Colon Cancer

Colon Cancer | Chemotherapy Effect | Chemotherapeutic Toxicity | MTHFR Gene Mutation

Costa Rica
Calithera Biosciences, Inc

Terminated

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE)

Non-Small Cell Lung Cancer | Non-squamous Non-small-cell Lung Cancer | Non-Squamous Non-Small Cell Neoplasm of Lung | KEAP1 Gene Mutation | NRF2 Gene Mutation | NFE2L2 Gene Mutation

United States
Piramal Enterprises Limited
Melanoma Research Foundation Breakthrough Consortium

Suspended

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Advanced or Inoperable Malignant Melanoma With BRAF Mutation

United States
Neuroscience Research Australia

Recruiting

TITAN Trial: Reducing Phantom Limb Pain in People With Amputations (TITAN)

Amputation | Phantom Limb Pain

Australia
National Cancer Institute (NCI)
Glaxosmithkline Biologicals S.A.

Terminated

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

Renal Failure | Solid Neoplasm | BRAF Gene Mutation | Hepatic Complication

United States, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR1 Gene Mutation | FGFR3 Gene Amplification

United States, Canada
Radiopharm Theranostics, Ltd

Recruiting

177Lu-anti-PD-L1 sdAb in Metastatic Non-small Cell Lung Cancer

Non Small Cell Lung Cancer | PDL1 Gene Mutation

Australia
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

FGFR2 Gene Mutation | Advanced Cholangiocarcinoma

Korea, Republic of, United States, Belgium, Spain, Taiwan, China, United Kingdom, France, Canada, Germany, Thailand, Italy, Portugal, Australia, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

Ductal Breast Carcinoma in Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in Situ

United States
Biogen
Ionis Pharmaceuticals, Inc.

Active, not recruiting

Long-Term Evaluation of BIIB067 (Tofersen)

ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

United States, Canada, Italy, Belgium, New Zealand, Japan, France, Germany, United Kingdom
TransThera Sciences (Nanjing), Inc.

Completed

Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Fusion | FGFR1 Alteration | FGFR3 Alteration

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Austrian Breast & Colorectal Cancer Study...

Recruiting

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation (BRCA-P)

Neoplasms | Breast Cancer | Breast Neoplasms | Breast Diseases | Breast Carcinoma | BRCA1 Mutation

United States
Recursion Pharmaceuticals Inc.

Recruiting

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

Solid Tumor | APC Gene Mutation | AXIN1 Gene Mutation

United States
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
Ascentage Pharma Group Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Melanoma | P53 Mutation | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Malignant Peripheral Nerve Sheath Tumors | MPNST | Unresectable or Metastatic Melanoma or Advanced Solid Tumors | MDM2 Gene Mutation

United States, Australia
Kura Oncology, Inc.

Recruiting

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Neoplasms by Histologic Type | Acute Myeloid Leukemia | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | AML | Acute Leukemia | Hematologic Malignancy | NPM1 Mutation | AML With Mutated NPM1 | KMT2Ar | MLL Rearrangement

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Ovarian Epithelial Tumor

United States
Puma Biotechnology, Inc.

Terminated

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations (SUMMIT)

Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

France, United States, Spain, Belgium, United Kingdom, Serbia, Australia, Israel, Canada, Denmark, Ireland, Italy, Korea, Republic of
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | FLT3 Gene Mutation | Acute Promyelocytic Leukemia With PML-RARA | Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1

United States
Plexxikon

Terminated

Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

Solid Tumor | Tenosynovial Giant Cell Tumor | Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations

United States
National Cancer Institute (NCI)

Completed

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Breast Carcinoma | Ovarian Carcinoma | Pancreatic Carcinoma | Prostate Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7 | EGFR Exon 19 Deletion Mutation | EGFR NP_005219.2:p.L858R

United States
AstraZeneca

Active, not recruiting

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Cervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 Positive

United States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
Relay Therapeutics, Inc.

Active, not recruiting

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, Adult

United States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

United States, Japan, Taiwan, Spain, Australia, Belgium, Canada, France, Germany, Italy, Korea, Republic of, Poland, United Kingdom
Turning Point Therapeutics, Inc.

Terminated

A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

Non-Small Cell Lung Cancer | NSCLC | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | ALK Gene Mutation

United States, Australia, Korea, Republic of
Rhythm Pharmaceuticals, Inc.

Completed

Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers

Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations

United States, Israel, Canada, Germany, Greece, Italy, Portugal
Novartis Pharmaceuticals

No longer available

Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy (AMLFLT3)

Acute Myeloid Leukemia (AML) With | FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)

United States
Inspirna, Inc.

Recruiting

A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Gastrointestinal Neoplasms | Colorectal Neoplasms | Gastric Cancer | Colorectal Cancer | Colorectal Cancer Metastatic | Gastrointestinal Cancer | Colorectal Carcinoma | CRC | KRAS Mutation-Related Tumors | Gastric Neoplasm

United States
Novartis Pharmaceuticals

Terminated

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (ReTHINK)

Myelofibrosis With High Molecular Risk Mutations

Belgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland

Clinical Trials on PIK3CA Mutation in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations